Vaxart, Inc. (VXRT) community

VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30

$0.48+0.02 (+5.04%)

Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –

Community

Notes and questions about Vaxart from other investors

No posts about VXRT yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Vaxart's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-11 reverse split on Feb 14, 2018
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VXRT.

Compare: VXRT vs VIR · VXRT vs VALN · VXRT vs NVAX · VXRT vs ALEC · VXRT vs FDMT

Revenue growth22.3% · median 151.2%

Operating margin16.6% · median -69.8%

Net margin16.0% · median -39.8%

Company	Revenue	Growth
NVAX	$411.65M	-61.3%
VIR	$302.80M	+1696.0%
VXRT	$181.27M	+22.3%
ALEC	$173.47M	+151.2%
VALN	€142.94M	-27.2%
FDMT	$96.06M	+79952.5%

Company

Next earnings (est.): Mar 11, 2027, during market hours
Exchange: OTC
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 65
Held by institutions: 0.0%
Auditor: WithumSmith+Brown, PC
SEC CIK: 72444

Advertisement
300 × 250

See a number that looks wrong?